Related Experiment Video
Updated: Jun 17, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Novel agents for relapsed and/or refractory multiple myeloma.
Sheeba K Thomas1, Tiffany A Richards, Donna M Weber
1Division of Cancer Medicine, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030-4009, USA. sthomas@mdanderson.org
Cancer Journal (Sudbury, Mass.)
|December 17, 2009
Summary
Novel agents like thalidomide, bortezomib, and lenalidomide have improved multiple myeloma treatment. Combinations offer higher response rates and survival for relapsed or refractory patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment has been revolutionized by novel therapeutic agents.
- Thalidomide, bortezomib, and lenalidomide offer new mechanisms for targeting multiple myeloma.
Purpose of the Study:
- To review the use of novel agents and their combinations in relapsed or refractory multiple myeloma.
- To highlight advancements in therapeutic options for multiple myeloma patients.
Main Methods:
- Review of existing literature on novel agents and combination therapies for multiple myeloma.
- Discussion of treatment strategies for frontline and relapsed/refractory patient populations.
Main Results:
- Novel agents and their combinations significantly increase response rates in multiple myeloma.
- These combinations have led to substantial improvements in median overall survival.
- Expanded treatment options are available for both initial therapy and relapsed/refractory cases.
Conclusions:
- Novel agents and combination therapies represent a significant advancement in multiple myeloma management.
- These strategies provide more effective treatment options, improving outcomes for patients with relapsed or refractory disease.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...